KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Non-Current Assets (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Non-Current Assets data on record, last reported at $7.5 billion in Q4 2025.

  • For Q4 2025, Non-Current Assets rose 1.49% year-over-year to $7.5 billion; the TTM value through Dec 2025 reached $30.1 billion, down 2.9%, while the annual FY2025 figure was $7.5 billion, 1.49% up from the prior year.
  • Non-Current Assets reached $7.5 billion in Q4 2025 per JAZZ's latest filing, down from $7.6 billion in the prior quarter.
  • Across five years, Non-Current Assets topped out at $10.3 billion in Q2 2021 and bottomed at -$2.5 billion in Q1 2022.
  • Average Non-Current Assets over 5 years is $7.3 billion, with a median of $7.8 billion recorded in 2022.
  • Peak YoY movement for Non-Current Assets: soared 172.55% in 2021, then plummeted 169.67% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $9.7 billion in 2021, then dropped by 15.05% to $8.2 billion in 2022, then fell by 3.3% to $8.0 billion in 2023, then dropped by 7.22% to $7.4 billion in 2024, then grew by 1.49% to $7.5 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $7.5 billion in Q4 2025, $7.6 billion in Q3 2025, and $7.6 billion in Q2 2025.